NASDAQ:MGTX MeiraGTx Q3 2026 Earnings Date & Estimates $9.89 +0.48 (+5.10%) Closing price 04:00 PM EasternExtended Trading$9.89 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MeiraGTx is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from MeiraGTx in Q3 2026MeiraGTx is expected to post earnings of -$0.46 per share on revenue of $6.95 million. In the same quarter a year earlier MeiraGTx reported -$0.62 per share on revenue of $0.41 million. MeiraGTx last reported on August 13, 2026, posting $1.71 per share and beating the -$0.4583 consensus estimate. MeiraGTx has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.46Expected Revenue$6.95 millionPrior-Year EPS-$0.62Prior-Year Revenue$0.41 millionExpected Revenue Growth+1,595.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$1.71 (Beat by +$2.1683)Last Quarter Revenue$321.43 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report MeiraGTx Q3 2026 Earnings FAQ When does MeiraGTx report Q3 2026 earnings? MeiraGTx (NASDAQ:MGTX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is MeiraGTx's Q3 2026 earnings call? MeiraGTx's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for MeiraGTx? Analysts expect MeiraGTx to post earnings of -$0.46 per share for Q3 2026. How much revenue is MeiraGTx expected to report? The consensus revenue estimate for MeiraGTx is $6.95 million for Q3 2026. MeiraGTx Earnings HeadlinesMeiraGTx: The Data Held Up, The Valuation Didn't (Rating Downgrade)October 14 at 10:37 AM | seekingalpha.comStoke Therapeutics (NASDAQ:STOK) vs. MeiraGTx (NASDAQ:MGTX) Critical ComparisonOctober 14 at 2:15 AM | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)MeiraGTx Holdings plc (MGTX)October 7, 2026 | finance.yahoo.comXenetic Biosciences (NASDAQ:XBIO) & MeiraGTx (NASDAQ:MGTX) Financial ContrastOctober 7, 2026 | americanbankingnews.comGoldman Sachs Initiates MeiraGTx at Neutral With $16 Price TargetSeptember 24, 2026 | marketscreener.comMSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX) (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function. The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment. MeiraGTx has also pursued additional programs in neurological and other serious diseases, although its pipeline and development priorities may change as clinical studies progress. Founded in 2015, MeiraGTx has built research, development and manufacturing capabilities in the United States and the United Kingdom. The company is led by Alexandra Forbes, who co-founded MeiraGTx and serves as president and chief executive officer.View MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
